The compromise of virtual screening and its impact on drug discovery

References

• Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57–74.
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Schlegl J, Hahne H, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509(7502):582–587.
   PubMed Web of Science ®Google Scholar
• Geiger T, Wehner A, Schaab C, et al. Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol Cell Proteomics. 2012;11(3):M111 014050.
   PubMed Web of Science ®Google Scholar
• Kim MS, Pinto SM, Getnet D, et al. A draft map of the human proteome. Nature. 2014;509(7502):575–581.
   PubMed Web of Science ®Google Scholar
• Mertins P, Qiao JW, Patel J, et al. Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods. 2013;10(7):634–637.
   PubMed Web of Science ®Google Scholar
• Moghaddas Gholami A, Hahne H, Wu Z, et al. Global proteome analysis of the nci-60 cell line panel. Cell Rep. 2013;4(3):609–620.
   PubMed Web of Science ®Google Scholar
• Shiromizu T, Adachi J, Watanabe S, et al. Identification of missing proteins in the nextprot database and unregistered phosphopeptides in the phosphositeplus database as part of the chromosome-centric human proteome project. J Proteome Res. 2013;12(6):2414–2421.
   PubMed Web of Science ®Google Scholar
• Law V, Knox C, Djoumbou Y, et al. Drugbank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42:D1091–D1097, Database issue
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of r&d costs. J Health Econ. 2016;47:20–33.
   PubMed Web of Science ®Google Scholar
• Kontoyianni M, Madhav P, Suchanek E, et al. Theoretical and practical considerations in virtual screening: A beaten field? Curr Med Chem. 2008;15(2):107–116.
   PubMed Web of Science ®Google Scholar
• Entzeroth M, Flotow H, Condron P. Overview of high-throughput screening. Curr Protoc Pharmacol 2009. Chapter 9: (Unit9.4).
   PubMedGoogle Scholar
• Schneider G. Virtual screening: an endless staircase? Nat Rev Drug Discov. 2010;9(4):273–276.
   PubMed Web of Science ®Google Scholar
• Warren GL, Andrews CW, Capelli AM, et al. A critical assessment of docking programs and scoring functions. J Med Chem. 2006;49(20):5912–5931.
   PubMed Web of Science ®Google Scholar
• Kolb P, Irwin JJ. Docking screens: right for the right reasons? Curr Top Med Chem. 2009;9(9):755–770.
   PubMed Web of Science ®Google Scholar
• Rueda M, Bottegoni G, Abagyan R. Recipes for the selection of experimental protein conformations for virtual screening. J Chem Inf Model. 2010;50(1):186–193.
   PubMed Web of Science ®Google Scholar
• Biesiada J, Porollo A, Velayutham P, et al. Survey of public domain software for docking simulations and virtual screening. Hum Genomics. 2011;5(5):497–505.
   PubMedGoogle Scholar
• Cheng T, Li Q, Zhou Z, et al. Structure-based virtual screening for drug discovery: A problem-centric review. Aaps J. 2012;14(1):133–141.
   PubMed Web of Science ®Google Scholar
• Kontoyianni M, McClellan LM, Sokol GS. Evaluation of docking performance: comparative data on docking algorithms. J Med Chem. 2004;47(3):558–565.
   PubMed Web of Science ®Google Scholar
• Kontoyianni M, Sokol GS, McClellan LM. Evaluation of library ranking efficacy in virtual screening. J Comput Chem. 2005;26(1):11–22.
   PubMed Web of Science ®Google Scholar
• Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: current status and future challenges. Proteins. 2006;65(1):15–26.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wong CF. Inexpensive method for selecting receptor structures for virtual screening. J Chem Inf Model. 2016;56(1):21–34.
   PubMed Web of Science ®Google Scholar
• Korb O, Olsson TS, Bowden SJ, et al. Potential and limitations of ensemble docking. J Chem Inf Model. 2012;52(5):1262–1274.
   PubMed Web of Science ®Google Scholar
• Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today. 2013;18(21–22):1067–1073.
   PubMed Web of Science ®Google Scholar
• Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507–519.
   PubMed Web of Science ®Google Scholar
• Wagner BK, Schreiber SL. The power of sophisticated phenotypic screening and modern mechanism-of-action methods. Cell Chem Biol. 2016;23(1):3–9.
   PubMed Web of Science ®Google Scholar
• Eder J, Sedrani R, Wiesmann C. The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov. 2014;13(8):577–587.
   PubMed Web of Science ®Google Scholar
• Lavecchia A, Di Giovanni C. Virtual screening strategies in drug discovery: A critical review. Curr Med Chem. 2013;20(23):2839–2860.
   PubMed Web of Science ®Google Scholar
• Meng XY, Zhang HX, Mezei M, et al. Molecular docking: A powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7(2):146–157.
   PubMed Web of Science ®Google Scholar
• Scior T, Bender A, Tresadern G, et al. Recognizing pitfalls in virtual screening: A critical review. J Chem Inf Model. 2012;52(4):867–881.
   PubMed Web of Science ®Google Scholar
• Moitessier N, Englebienne P, Lee D, et al. Towards the development of universal, fast and highly accurate docking/scoring methods: A long way to go. Br J Pharmacol. 2008;153(Suppl 1):S7–S26.
   PubMed Web of Science ®Google Scholar
• Lionta E, Spyrou G, Vassilatis DK, et al. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem. 2014;14(16):1923–1938.
   PubMed Web of Science ®Google Scholar
• Damm-Ganamet KL, Smith RD, Dunbar JB Jr., et al. Csar benchmark exercise 2011-2012: evaluation of results from docking and relative ranking of blinded congeneric series. J Chem Inf Model. 2013;53(8):1853–1870.
   PubMed Web of Science ®Google Scholar
• Zhu T, Cao S, Su PC, et al. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J Med Chem. 2013;56(17):6560–6572.
   PubMed Web of Science ®Google Scholar
• Ripphausen P, Nisius B, Peltason L, et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications. J Med Chem. 2010;53(24):8461–8467.
   PubMed Web of Science ®Google Scholar
• Drwal MN, Marinello J, Manzo SG, et al. Novel DNA topoisomerase iialpha inhibitors from combined ligand- and structure-based virtual screening. PLoS One. 2014;9(12):e114904.
   PubMed Web of Science ®Google Scholar
• Sharma RK, Younis Y, Mugumbate G, et al. Synthesis and structure-activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the plasmodium falciparum cysteine protease falcipain-2. Eur J Med Chem. 2015;90(27 Jan):507–518.
   PubMedGoogle Scholar
• Chen H, Knerr L, Akerud T, et al. Discovery of a novel pyrazole series of group x secreted phospholipase a2 inhibitor (spla2x) via fragment based virtual screening. Bioorg Med Chem Lett. 2014;24(22):5251–5255.
   PubMed Web of Science ®Google Scholar
• Park H, Park SY, Nam SW, et al. Discovery of novel dusp16 phosphatase inhibitors through virtual screening with homology modeled protein structure. J Biomol Screen. 2014;19(10):1383–1390.
   PubMedGoogle Scholar
• Wang L, Si P, Sheng Y, et al. Discovery of new non-steroidal farnesoid x receptor modulators through 3d shape similarity search and structure-based virtual screening. Chem Biol Drug Des. 2015;85(4):481–487.
   PubMed Web of Science ®Google Scholar
• Gu WG, Zhang X, Ip DT, et al. Discovery of a novel hiv-1 integrase inhibitor from natural compounds through structure based virtual screening and cell imaging. FEBS Lett. 2014;588(18):3461–3468.
   PubMed Web of Science ®Google Scholar
• Chen F, Liu J, Huang M, et al. Identification of a new rxralpha antagonist targeting the coregulator-binding site. ACS Med Chem Lett. 2014;5(7):736–741.
   PubMed Web of Science ®Google Scholar
• Jeankumar VU, Renuka J, Kotagiri S, et al. Gyrase atpase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues. ChemMedChem. 2014;9(8):1850–1859.
   PubMed Web of Science ®Google Scholar
• Tanwar O, Tanwar L, Shaquiquzzaman M, et al. Structure based virtual screening of mdpi database: discovery of structurally diverse and novel dpp-iv inhibitors. Bioorg Med Chem Lett. 2014;24(15):3447–3451.
   PubMed Web of Science ®Google Scholar
• Kasam V, Lee NR, Kim KB, et al. Selective immunoproteasome inhibitors with non-peptide scaffolds identified from structure-based virtual screening. Bioorg Med Chem Lett. 2014;24(15):3614–3617.
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang Y, Zheng L, et al. Discovery of novel inhibitors targeting the macrophage migration inhibitory factor via structure-based virtual screening and bioassays. J Med Chem. 2014;57(9):3737–3745.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xue X, Jin X, et al. Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new rorgamma inhibitors using virtual screening, synthesis and biological evaluation. Eur J Med Chem. 2014;78:431–441.
   PubMed Web of Science ®Google Scholar
• Zhong HJ, Liu LJ, Chong CM, et al. Discovery of a natural product-like inos inhibitor by molecular docking with potential neuroprotective effects in vivo. PLoS One. 2014;9(4):e92905.
   PubMed Web of Science ®Google Scholar
• Kumar A, Ito A, Takemoto M, et al. Identification of 1,2,5-oxadiazoles as a new class of senp2 inhibitors using structure based virtual screening. J Chem Inf Model. 2014;54(3):870–880.
   PubMed Web of Science ®Google Scholar
• Lagos CF, Vecchiola A, Allende F, et al. Identification of novel 11beta-hsd1 inhibitors by combined ligand- and structure-based virtual screening. Mol Cell Endocrinol. 2014;384(1–2):71–82.
   PubMed Web of Science ®Google Scholar
• Deng X, Lin F, Zhang Y, et al. Identification of small molecule sphingomyelin synthase inhibitors. Eur J Med Chem. 2014;73(12 Feb):1–7.
   PubMedGoogle Scholar
• Pan P, Tian S, Sun H, et al. Identification and preliminary sar analysis of novel type-i inhibitors of tie-2 via structure-based virtual screening and biological evaluation in in vitro models. J Chem Inf Model. 2015;55(12):2693–2704.
   PubMed Web of Science ®Google Scholar
• Ren Z, Cui T, Zeng J, et al. Molecule targeting glucosyltransferase inhibits streptococcus mutans biofilm formation and virulence. Antimicrob Agents Chemother. 2016;60(1):126–135.
   PubMed Web of Science ®Google Scholar
• Pallandre JR, Borg C, Rognan D, et al. Novel aminotetrazole derivatives as selective stat3 non-peptide inhibitors. Eur J Med Chem. 2015;103(20 Oct):163–174.
   PubMedGoogle Scholar
• Li YL, Qi XY, Jiang H, et al. Discovery, synthesis and biological evaluation of 2-(4-(n-phenethylsulfamoyl)phenoxy)acetamides (sapas) as novel sphingomyelin synthase 1 inhibitors. Bioorg Med Chem. 2015;23(18):6173–6184.
   PubMed Web of Science ®Google Scholar
• Muralidharan AR, Selvaraj C, Singh SK, et al. Structure-based virtual screening and biological evaluation of a calpain inhibitor for prevention of selenite-induced cataractogenesis in an in vitro system. J Chem Inf Model. 2015;55(8):1686–1697.
   PubMed Web of Science ®Google Scholar
• Lin SH, Huang KJ, Weng CF, et al. Exploration of natural product ingredients as inhibitors of human hmg-coa reductase through structure-based virtual screening. Drug Des Devel Ther. 2015;9(26 June):3313–3324.
   PubMedGoogle Scholar
• Pesapane A, Di Giovanni C, Rossi FW, et al. Discovery of new small molecules inhibiting 67 kda laminin receptor interaction with laminin and cancer cell invasion. Oncotarget. 2015;6(20):18116–18133.
   PubMedGoogle Scholar
• Lin A, Cai Z, Hu G, et al. Identification of alk5 inhibitor via structure-based virtual screening and admet prediction. J Recept Signal Transduct Res. 2015;35(6):559–564.
   PubMed Web of Science ®Google Scholar
• Evelyn CR, Biesiada J, Duan X, et al. Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a ras-activating enzyme. J Biol Chem. 2015;290(20):12879–12898.
   PubMed Web of Science ®Google Scholar
• Sindhu T, Srinivasan P. Identification of potential dual agonists of fxr and tgr5 using e-pharmacophore based virtual screening. Mol Biosyst. 2015;11(5):1305–1318.
   PubMedGoogle Scholar
• Maltarollo VG, Togashi M, Nascimento AS, et al. Structure-based virtual screening and discovery of new ppardelta/gamma dual agonist and ppardelta and gamma agonists. PLoS One. 2015;10(3):e0118790.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Y, Sun R, et al. Discovery of novel antagonists of glycoprotein iib/iiia-mediated platelet aggregation through virtual screening. Bioorg Med Chem Lett. 2015;25(6):1249–1253.
   PubMed Web of Science ®Google Scholar
• Chuang CH, Cheng TC, Leu YL, et al. Discovery of akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents. Int J Mol Sci. 2015;16(2):3202–3212.
   PubMed Web of Science ®Google Scholar
• Dighe SN, Deora GS, De la Mora E, et al. Discovery and structure-activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening. J Med Chem. 2016;59(16):7683–7689.
   PubMed Web of Science ®Google Scholar
• Guerreiro PS, Estacio SG, Antunes F, et al. Structure-based virtual screening toward the discovery of novel inhibitors of the DNA repair activity of the human apurinic/apyrimidinic endonuclease 1. Chem Biol Drug Des. 2016;88(6):915–925.
   PubMed Web of Science ®Google Scholar
• Lu P, Liu X, Yuan X, et al. Discovery of a novel nedd8 activating enzyme inhibitor with piperidin-4-amine scaffold by structure-based virtual screening. ACS Chem Biol. 2016;11(7):1901–1907.
   PubMed Web of Science ®Google Scholar
• Gao N, Ren J, Hou L, et al. Identification of novel potent human testis-specific and bromodomain-containing protein (brdt) inhibitors using crystal structure-based virtual screening. Int J Mol Med. 2016;38(1):39–44.
   PubMed Web of Science ®Google Scholar
• Chen S, Li L, Chen Y, et al. Identification of novel disruptor of telomeric silencing 1-like (dot1l) inhibitors through structure-based virtual screening and biological assays. J Chem Inf Model. 2016;56(3):527–534.
   PubMed Web of Science ®Google Scholar
• Ma GH, Ye Y, Zhang D, et al. Identification and biochemical characterization of dc07090 as a novel potent small molecule inhibitor against human enterovirus 71 3c protease by structure-based virtual screening. Eur J Med Chem. 2016;124:981–991.
   PubMed Web of Science ®Google Scholar
• Rodriguez D, Chakraborty S, Warnick E, et al. Structure-based screening of uncharted chemical space for atypical adenosine receptor agonists. ACS Chem Biol. 2016;11(10):2763–2772.
   PubMed Web of Science ®Google Scholar
• Di Giovanni C, Ettari R, Sarno S, et al. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening. Eur J Med Chem. 2016;121:578–591.
   PubMed Web of Science ®Google Scholar
• Sun H, Pan P, Tian S, et al. Constructing and validating high-performance miec-svm models in virtual screening for kinases: a better way for actives discovery. Sci Rep. 2016;6:24817.
   PubMed Web of Science ®Google Scholar
• Ye F, Zhang W, Lu W, et al. Identification of novel inhibitors against coactivator associated arginine methyltransferase 1 based on virtual screening and biological assays. Biomed Res Int. 2016;2016:7086390.
   PubMedGoogle Scholar
• Kondengaden SM, Luo LF, Huang K, et al. Discovery of novel small molecule inhibitors of lysine methyltransferase g9a and their mechanism in leukemia cell lines. Eur J Med Chem. 2016;122(21 Oct):382–393.
   PubMedGoogle Scholar
• Li T, Yin N, Liu H, et al. Novel inhibitors of toxin hipa reduce multidrug tolerant persisters. ACS Med Chem Lett. 2016;7(5):449–453.
   PubMed Web of Science ®Google Scholar
• De Falco F, Di Giovanni C, Cerchia C, et al. Novel non-peptide small molecules preventing ikkbeta/nemo association inhibit nf-kappab activation in lps-stimulated j774 macrophages. Biochem Pharmacol. 2016;104(15 March):83–94.
   PubMedGoogle Scholar
• Pan P, Sun H, Liu H, et al. In silico exploration for novel type-i inhibitors of tie-2/tek: the performance of different selection strategy in selecting virtual screening candidates. Sci Rep. 2016;6(23 Nov):37628.
   PubMedGoogle Scholar
• Beccari AR, Gemei M, Lo Monte M, et al. Novel selective, potent naphthyl trpm8 antagonists identified through a combined ligand- and structure-based virtual screening approach. Sci Rep. 2017;7(1):10999.
   PubMedGoogle Scholar
• Liu Y, Ren Y, Cao Y, et al. Discovery of a low toxicity o-glcnac transferase (ogt) inhibitor by structure-based virtual screening of natural products. Sci Rep. 2017;7(1):12334.
   PubMedGoogle Scholar
• Kumar R, Kumar A, Langstrom B, et al. Discovery of novel choline acetyltransferase inhibitors using structure-based virtual screening. Sci Rep. 2017;7(1):16287.
   PubMedGoogle Scholar
• Shao Z, Xu P, Xu W, et al. Discovery of novel DNA methyltransferase 3a inhibitors via structure-based virtual screening and biological assays. Bioorg Med Chem Lett. 2017;27(2):342–346.
   PubMed Web of Science ®Google Scholar
• Min Q, Cai X, Sun W, et al. Identification of mangiferin as a potential glucokinase activator by structure-based virtual ligand screening. Sci Rep. 2017;7(20 March):44681.
   PubMedGoogle Scholar
• Ortore G, Martinelli A. Identification of transthyretin fibril formation inhibitors using structure-based virtual screening. ChemMedChem. 2017;12(16):1327–1334.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang Y, Fan K, et al. Discovery of new syk inhibitors through structure-based virtual screening. Bioorg Med Chem Lett. 2017;27(8):1776–1779.
   PubMed Web of Science ®Google Scholar
• Zhang C, Feng LJ, Huang Y, et al. Discovery of novel phosphodiesterase-2a inhibitors by structure-based virtual screening, structural optimization, and bioassay. J Chem Inf Model. 2017;57(2):355–364.
   PubMed Web of Science ®Google Scholar
• Chen S, Feng Z, Wang Y, et al. Discovery of novel ligands for tnf-alpha and tnf receptor-1 through structure-based virtual screening and biological assay. J Chem Inf Model. 2017;57(5):1101–1111.
   PubMed Web of Science ®Google Scholar
• Spyrakis F, Celenza G, Marcoccia F, et al. Structure-based virtual screening for the discovery of novel inhibitors of new delhi metallo-beta-lactamase-1. ACS Med Chem Lett. 2018;9(1):45–50.
   PubMed Web of Science ®Google Scholar
• Rudling A, Gustafsson R, Almlof I, et al. Fragment-based discovery and optimization of enzyme inhibitors by docking of commercial chemical space. J Med Chem. 2017;60(19):8160–8169.
   PubMed Web of Science ®Google Scholar
• Soubhye J, Chikh Alard I, Aldib I, et al. Discovery of novel potent reversible and irreversible myeloperoxidase inhibitors using virtual screening procedure. J Med Chem. 2017;60(15):6563–6586.
   PubMed Web of Science ®Google Scholar
• Mannel B, Jaiteh M, Zeifman A, et al. Structure-guided screening for functionally selective d2 dopamine receptor ligands from a virtual chemical library. ACS Chem Biol. 2017;12(10):2652–2661.
   PubMed Web of Science ®Google Scholar
• Segura-Cabrera A, Tripathi R, Zhang X, et al. A structure- and chemical genomics-based approach for repositioning of drugs against vcp/p97 atpase. Sci Rep. 2017;7:44912.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun Y, Cao R, et al. In silico identification of a novel hinge-binding scaffold for kinase inhibitor discovery. J Med Chem. 2017;60(20):8552–8564.
   PubMed Web of Science ®Google Scholar
• Zhang W, Lu W, Ananthan S, et al. Discovery of novel frizzled-7 inhibitors by targeting the receptor‘s transmembrane domain. Oncotarget. 2017;8(53):91459–91470.
   PubMedGoogle Scholar
• Ekhteiari Salmas R, Unlu A, Bektas M, et al. Virtual screening of small molecules databases for discovery of novel parp-1 inhibitors: combination of in silico and in vitro studies. J Biomol Struct Dyn. 2017;35(9):1899–1915.
   PubMed Web of Science ®Google Scholar
• Bi Y, Might M, Vankayalapati H, et al. Repurposing of proton pump inhibitors as first identified small molecule inhibitors of endo-beta-n-acetylglucosaminidase (engase) for the treatment of ngly1 deficiency, a rare genetic disease. Bioorg Med Chem Lett. 2017;27(13):2962–2966.
   PubMed Web of Science ®Google Scholar
• Villoutreix BO, Khatib AM, Cheng Y, et al. Blockade of the malignant phenotype by beta-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes. Oncotarget. 2017;8(6):10437–10449.
   PubMedGoogle Scholar
• Dou X, Jiang L, Wang Y, et al. Discovery of new gsk-3beta inhibitors through structure-based virtual screening. Bioorg Med Chem Lett. 2018;28(2):160–166.
   PubMed Web of Science ®Google Scholar
• Ramezani M, Shamsara J. An integrated structure- and pharmacophore-based mmp-12 virtual screening. Mol Divers. 2018;22(2):383–395.
   PubMed Web of Science ®Google Scholar
• Qiu X, Huang Y, Wu D, et al. Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (pde2) inhibitors: structure-based virtual screening, optimization and biological evaluation. Bioorg Med Chem. 2018;26(1):119–133.
   PubMed Web of Science ®Google Scholar
• Lu W, Zhang D, Ma H, et al. Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays. Eur J Med Chem. 2018;155(15 July):34–48.
   PubMedGoogle Scholar
• Naz S, Farooq U, Ali S, et al. Identification of new benzamide inhibitor against alpha-subunit of tryptophan synthase from mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations. J Biomol Struct Dyn. 2019;37(4):1043–1053.
   PubMed Web of Science ®Google Scholar
• Bollini M, Leal ES, Adler NS, et al. Discovery of novel bovine viral diarrhea inhibitors using structure-based virtual screening on the envelope protein e2. Front Chem. 2018;6(26 March):79.
   PubMedGoogle Scholar
• Li Y, Pu Y, Liu H, et al. Discovery of novel wee1 inhibitors via structure-based virtual screening and biological evaluation. J Comput Aided Mol Des. 2018;32(9):901–915.
   PubMed Web of Science ®Google Scholar
• Grabowski M, Murgueitio MS, Bermudez M, et al. Identification of a pyrogallol derivative as a potent and selective human tlr2 antagonist by structure-based virtual screening. Biochem Pharmacol. 2018;154:148–160.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan C, Mary Thangakani A, Velmurugan D, et al. Identification of type i and type ii inhibitors of c-yes kinase using in silico and experimental techniques. J Biomol Struct Dyn. 2018;36(6):1566–1576.
   PubMed Web of Science ®Google Scholar
• Szilagyi B, Skok Z, Racz A, et al. Discovery of d-amino acid oxidase inhibitors based on virtual screening against the lid-open enzyme conformation. Bioorg Med Chem Lett. 2018;28(10):1693–1698.
   PubMed Web of Science ®Google Scholar
• Dong G, Wu Y, Sun Y, et al. Identification of potent catalytic inhibitors of human DNA topoisomerase ii by structure-based virtual screening. Medchemcomm. 2018;9(7):1142–1146.
   PubMed Web of Science ®Google Scholar
• Singh S, Khare G, Bahal RK, et al. Identification of mycobacterium tuberculosis bioa inhibitors by using structure-based virtual screening. Drug Des Devel Ther. 2018;12(1 May):1065–1079.
   PubMedGoogle Scholar
• Merzoug A, Chikhi A, Bensegueni A, et al. Virtual screening approach of bacterial peptide deformylase inhibitors results in new antibiotics. Mol Inform. 2018;37(9 Oct):1700087.
   Google Scholar
• Chen Z, Cen X, Yang J, et al. Structure-based discovery of a specific tlr1-tlr2 small molecule agonist from the zinc drug library database. Chem Commun (Camb). 2018;54(81):11411–11414.
   PubMed Web of Science ®Google Scholar
• Wang Q, Xu J, Li Y, et al. Identification of a novel protein arginine methyltransferase 5 inhibitor in non-small cell lung cancer by structure-based virtual screening. Front Pharmacol. 2018;9(1 March):173.
   PubMedGoogle Scholar
• Diao Y, Jiang J, Zhang S, et al. Discovery of natural products as novel and potent fxr antagonists by virtual screening. Front Chem. 2018;6(140):30 April.
   Google Scholar
• Zhou S, Li GB, Luo L, et al. Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors. Org Biomol Chem. 2018;16(9):1489–1495.
   PubMed Web of Science ®Google Scholar
• Shamsara J. Identification of non-zinc binding inhibitors of mmp-2 through virtual screening and subsequent rescoring. Drug Res (Stuttg). 2018;68(9):529–535.
   PubMed Web of Science ®Google Scholar
• Kalash L, Cresser-Brown J, Habchi J, et al. Structure-based design of allosteric calpain-1 inhibitors populating a novel bioactivity space. Eur J Med Chem. 2018;157:1264–1275.
   PubMed Web of Science ®Google Scholar
• Liang J, Li X, Yang S, et al. Design, synthesis and biological evaluation of uracil derivatives as novel vegfr-2 inhibitors. Curr Pharm Des. 2018;24(6):734–740.
   PubMed Web of Science ®Google Scholar
• Shi X, Li H, Shi A, et al. Discovery of rafoxanide as a dual cdk4/6 inhibitor for the treatment of skin cancer. Oncol Rep. 2018;40(3):1592–1600.
   PubMed Web of Science ®Google Scholar
• Jaiteh M, Zeifman A, Saarinen M, et al. Docking screens for dual inhibitors of disparate drug targets for parkinson‘s disease. J Med Chem. 2018;61(12):5269–5278.
   PubMed Web of Science ®Google Scholar
• Li Y, Bao M, Yang C, et al. Computer-aided identification of a novel pyruvate kinase m2 activator compound. Cell Prolif. 2018;51(6):e12509.
   PubMed Web of Science ®Google Scholar
• Lin TE, HuangFu WC, Chao MW, et al. A novel selective jak2 inhibitor identified using pharmacological interactions. Front Pharmacol. 2018;9(4 Dec):1379.
   PubMedGoogle Scholar
• Ahn SH, Lee JK, Kim ND, et al. Dpie [2-(1,2-diphenyl-1h-indol-3-yl)ethanamine] augments pro-inflammatory cytokine production in il-1beta-stimulated primary human oral cells. Int J Mol Sci. 2018;19(7):1835.
   Web of Science ®Google Scholar
• Kuenemann MA, Spears PA, Orndorff PE, et al. In silico predicted glucose-1-phosphate uridylyltransferase (galu) inhibitors block a key pathway required for listeria virulence. Mol Inform. 2018;37(6–7):e1800004.
   PubMed Web of Science ®Google Scholar
• Libby CJ, Zhang S, Benavides GA, et al. Identification of compounds that decrease glioblastoma growth and glucose uptake in vitro. ACS Chem Biol. 2018;13(8):2048–2057.
   PubMed Web of Science ®Google Scholar
• Hu XM, Dong W, Cui ZW, et al. In silico identification of ache and parp-1 dual-targeted inhibitors of alzheimer‘s disease. J Mol Model. 2018;24(7):151.
   PubMed Web of Science ®Google Scholar
• Damani Shah H, Saranath D, Das S, et al. In-silico identification of small molecules targeting h-ras and in-vitro cytotoxicity with caspase-mediated apoptosis in carcinoma cells. J Cell Biochem. 2019;120(4):5519–5530.
   PubMed Web of Science ®Google Scholar
• Liu YL, Lindert S, Zhu W, et al. Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site. Proc Natl Acad Sci U S A. 2014;111(25):E2530–E2539.
   PubMed Web of Science ®Google Scholar
• Lopez-Munoz F, Alamo C, Garcia-Garcia P. The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs. J Anxiety Disord. 2011;25(4):554–562.
   PubMed Web of Science ®Google Scholar
• Palmer WS, Poncet-Montange G, Liu G, et al. Structure-guided design of iacs-9571, a selective high-affinity dual trim24-brpf1 bromodomain inhibitor. J Med Chem. 2016;59(4):1440–1454.
   PubMed Web of Science ®Google Scholar
• Marchand JR, Lolli G, Caflisch A. Derivatives of 3-amino-2-methylpyridine as baz2b bromodomain ligands: in silico discovery and in crystallo validation. J Med Chem. 2016;59(21):9919–9927.
   PubMed Web of Science ®Google Scholar
• Chang CK, Jeyachandran S, Hu NJ, et al. Structure-based virtual screening and experimental validation of the discovery of inhibitors targeted towards the human coronavirus nucleocapsid protein. Mol Biosyst. 2016;12(1):59–66.
   PubMedGoogle Scholar
• Lee HJ, Bao J, Miller A, et al. Structure-based discovery of novel small molecule wnt signaling inhibitors by targeting the cysteine-rich domain of frizzled. J Biol Chem. 2015;290(51):30596–30606.
   PubMed Web of Science ®Google Scholar
• Macarron R, Banks MN, Bojanic D, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov. 2011;10(3):188–195.
   PubMed Web of Science ®Google Scholar
• Babaoglu K, Simeonov A, Irwin JJ, et al. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J Med Chem. 2008;51(8):2502–2511.
   PubMed Web of Science ®Google Scholar
• Doman TN, McGovern SL, Witherbee BJ, et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1b. J Med Chem. 2002;45(11):2213–2221.
   PubMed Web of Science ®Google Scholar
• Ferreira RS, Simeonov A, Jadhav A, et al. Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem. 2010;53(13):4891–4905.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4(2):67–73.
   PubMed Web of Science ®Google Scholar
• Shum D, Bhinder B, Radu C, et al. An image-based biosensor assay strategy to screen for modulators of the microrna 21 biogenesis pathway. Comb Chem High Throughput Screen. 2012;15(7):529–541.
   PubMed Web of Science ®Google Scholar
• Malo N, Hanley JA, Carlile G, et al. Experimental design and statistical methods for improved hit detection in high-throughput screening. J Biomol Screen. 2010;15(8):990–1000.
   PubMedGoogle Scholar
• Malo N, Hanley JA, Cerquozzi S, et al. Statistical practice in high-throughput screening data analysis. Nat Biotechnol. 2006;24(2):167–175.
   PubMed Web of Science ®Google Scholar
• Brideau C, Gunter B, Pikounis B, et al. Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen. 2003;8(6):634–647.
   PubMedGoogle Scholar
• Mayr LM, Fuerst P. The future of high-throughput screening. J Biomol Screen. 2008;13(6):443–448.
   PubMedGoogle Scholar
• Posner BA, Xi H, Mills JE. Enhanced hts hit selection via a local hit rate analysis. J Chem Inf Model. 2009;49(10):2202–2210.
   PubMed Web of Science ®Google Scholar
• Wunberg T, Hendrix M, Hillisch A, et al. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov Today. 2006;11(3–4):175–180.
   PubMed Web of Science ®Google Scholar
• Hansson M, Pemberton J, Engkvist O, et al. On the relationship between molecular hit rates in high-throughput screening and molecular descriptors. J Biomol Screen. 2014;19(5):727–737.
   PubMedGoogle Scholar
• Dahlin JL, Walters MA. The essential roles of chemistry in high-throughput screening triage. Future Med Chem. 2014;6(11):1265–1290.
   PubMed Web of Science ®Google Scholar
• St-Gallay SA, Bennett N, Critchlow SE, et al. A high-throughput screening triage workflow to authenticate a novel series of pfkfb3 inhibitors. SLAS Discov. 2018;23(1):11–22.
   PubMed Web of Science ®Google Scholar
• Walters WP. Virtual chemical libraries. J Med Chem. 2019;62(3):1116–1124.
   PubMed Web of Science ®Google Scholar
• Su M, Yang Q, Du Y, et al. Comparative assessment of scoring functions: the casf-2016 update. J Chem Inf Model. 2019;59(2):895–913.
   PubMed Web of Science ®Google Scholar
• Klon AE, Glick M, Thoma M, et al. Finding more needles in the haystack: A simple and efficient method for improving high-throughput docking results. J Med Chem. 2004;47(11):2743–2749.
   PubMed Web of Science ®Google Scholar
• Nicholls A. What do we know and when do we know it? J Comput Aided Mol Des. 2008;22(3–4):239–255.
   PubMed Web of Science ®Google Scholar
• Hawkins PC, Warren GL, Skillman AG, et al. How to do an evaluation: pitfalls and traps. J Comput Aided Mol Des. 2008;22(3–4):179–190.
   PubMed Web of Science ®Google Scholar
• Halgren TA, Murphy RB, Friesner RA, et al. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47(7):1750–1759.
   PubMed Web of Science ®Google Scholar
• Kairys V, Fernandes MX, Gilson MK. Screening drug-like compounds by docking to homology models: A systematic study. J Chem Inf Model. 2006;46(1):365–379.
   PubMed Web of Science ®Google Scholar
• Seifert MH. Assessing the discriminatory power of scoring functions for virtual screening. J Chem Inf Model. 2006;46(3):1456–1465.
   PubMed Web of Science ®Google Scholar
• Truchon JF, Bayly CI. Glare: A new approach for filtering large reagent lists in combinatorial library design using product properties. J Chem Inf Model. 2006;46(4):1536–1548.
   PubMed Web of Science ®Google Scholar
• Fox S, Farr-Jones S, Sopchak L, et al. High-throughput screening: update on practices and success. J Biomol Screen. 2006;11(7):864–869.
   PubMed Web of Science ®Google Scholar
• Bleicher KH, Bohm HJ, Muller K, et al. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov. 2003;2(5):369–378.
   PubMed Web of Science ®Google Scholar
• Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475–486.
   PubMed Web of Science ®Google Scholar
• Arrowsmith J. Trial watch: phase ii failures: 2008-2010. Nat Rev Drug Discov. 2011;10(5):328–329.
   PubMed Web of Science ®Google Scholar
• Arrowsmith J. Trial watch: phase iii and submission failures: 2007-2010. Nat Rev Drug Discov. 2011;10(2):87.
   PubMed Web of Science ®Google Scholar
• Ganser LR, Lee J, Rangadurai A, et al. High-performance virtual screening by targeting a high-resolution rna dynamic ensemble. Nat Struct Mol Biol. 2018;25(5):425–434.
   PubMed Web of Science ®Google Scholar
• Damm-Ganamet KL, Bembenek SD, Venable JW, et al. A prospective virtual screening study: enriching hit rates and designing focus libraries to find inhibitors of pi3kdelta and pi3kgamma. J Med Chem. 2016;59(9):4302–4313.
   PubMed Web of Science ®Google Scholar
• Cai H, Liu Q, Gao D, et al. Novel fatty acid binding protein 4 (fabp4) inhibitors: virtual screening, synthesis and crystal structure determination. Eur J Med Chem. 2015;90(27 January):241–250.
   PubMedGoogle Scholar
• Xue X, Zhang Y, Liu Z, et al. Discovery of benzo[cd]indol-2(1h)-ones as potent and specific bet bromodomain inhibitors: structure-based virtual screening, optimization, and biological evaluation. J Med Chem. 2016;59(4):1565–1579.
   PubMed Web of Science ®Google Scholar
• Mao R, Shao J, Zhu K, et al. Potent, selective, and cell active protein arginine methyltransferase 5 (prmt5) inhibitor developed by structure-based virtual screening and hit optimization. J Med Chem. 2017;60(14):6289–6304.
   PubMed Web of Science ®Google Scholar
• Waszkowycz B, Smith KM, McGonagle AE, et al. Cell-active small molecule inhibitors of the DNA-damage repair enzyme poly(adp-ribose) glycohydrolase (parg): discovery and optimization of orally bioavailable quinazolinedione sulfonamides. J Med Chem. 2018;61(23):10767–10792.
   PubMed Web of Science ®Google Scholar
• Pantsar T, Singha P, Nevalainen TJ, et al. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors. Eur J Pharm Sci. 2017;107(30 Sep):97–111.
   PubMedGoogle Scholar
• Pandey P, Roy KK, Liu H, et al. Structure-based identification of potent natural product chemotypes as cannabinoid receptor 1 inverse agonists. Molecules. 2018;23(10):2630.
   Web of Science ®Google Scholar
• Park H, Jung HY, Mah S, et al. Systematic computational design and identification of low picomolar inhibitors of aurora kinase a. J Chem Inf Model. 2018;58(3):700–709.
   PubMed Web of Science ®Google Scholar
• Park H, Lee S, Suh J. Structural and dynamical basis of broad substrate specificity, catalytic mechanism, and inhibition of cytochrome p450 3a4. J Am Chem Soc. 2005;127(39):13634–13642.
   PubMed Web of Science ®Google Scholar
• Park H, Shin Y, Choe H, et al. Computational design and discovery of nanomolar inhibitors of ikappab kinase beta. J Am Chem Soc. 2015;137(1):337–348.
   PubMed Web of Science ®Google Scholar
• Shin S, Mah S, Hong S, et al. Discovery of low micromolar dual inhibitors for wild type and l1196m mutant of anaplastic lymphoma kinase through structure-based virtual screening. J Chem Inf Model. 2016;56(4):802–810.
   PubMed Web of Science ®Google Scholar
• Ferreira LLG, Ferreira RS, Palomino DL, et al. Structure-based virtual screening and biochemical evaluation for the identification of novel trypanosoma brucei aldolase inhibitors. Curr Top Med Chem. 2018;18(5):397–405.
   PubMed Web of Science ®Google Scholar
• Abel R, Young T, Farid R, et al. Role of the active-site solvent in the thermodynamics of factor xa ligand binding. J Am Chem Soc. 2008;130(9):2817–2831.
   PubMed Web of Science ®Google Scholar
• Young T, Abel R, Kim B, et al. Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc Natl Acad Sci U S A. 2007;104(3):808–813.
   PubMed Web of Science ®Google Scholar
• Guimaraes CR, Mathiowetz AM. Addressing limitations with the mm-gb/sa scoring procedure using the watermap method and free energy perturbation calculations. J Chem Inf Model. 2010;50(4):547–559.
   PubMed Web of Science ®Google Scholar
• Abel R, Salam NK, Shelley J, et al. Contribution of explicit solvent effects to the binding affinity of small-molecule inhibitors in blood coagulation factor serine proteases. ChemMedChem. 2011;6(6):1049–1066.
   PubMed Web of Science ®Google Scholar
• Ross GA, Morris GM, Biggin PC. Rapid and accurate prediction and scoring of water molecules in protein binding sites. PLoS One. 2012;7(3):e32036.
   PubMed Web of Science ®Google Scholar
• Wong SE, Lightstone FC. Accounting for water molecules in drug design. Expert Opin Drug Discov. 2011;6(1):65–74.
   PubMed Web of Science ®Google Scholar
• Forli S, Olson AJ. A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking. J Med Chem. 2012;55(2):623–638.
   PubMed Web of Science ®Google Scholar
• Verdonk ML, Chessari G, Cole JC, et al. Modeling water molecules in protein-ligand docking using gold. J Med Chem. 2005;48(20):6504–6515.
   PubMed Web of Science ®Google Scholar
• Huang N, Shoichet BK. Exploiting ordered waters in molecular docking. J Med Chem. 2008;51(16):4862–4865.
   PubMed Web of Science ®Google Scholar
• Zheng M, Li Y, Xiong B, et al. Water pmf for predicting the properties of water molecules in protein binding site. J Comput Chem. 2013;34(7):583–592.
   PubMed Web of Science ®Google Scholar
• Corbeil CR, Englebienne P, Yannopoulos CG, et al. Docking ligands into flexible and solvated macromolecules. 2. Development and application of fitted 1.5 to the virtual screening of potential hcv polymerase inhibitors. J Chem Inf Model. 2008;48(4):902–909.
   PubMed Web of Science ®Google Scholar
• Lovell SC, Word JM, Richardson JS, et al. The penultimate rotamer library. Proteins. 2000;40(3):389–408.
   PubMed Web of Science ®Google Scholar
• Leach AR. Ligand docking to proteins with discrete side-chain flexibility. J Mol Biol. 1994;235(1):345–356.
   PubMed Web of Science ®Google Scholar
• Desmet J, Wilson IA, Joniau M, et al. Computation of the binding of fully flexible peptides to proteins with flexible side chains. FASEB J. 1997;11(2):164–172.
   PubMed Web of Science ®Google Scholar
• Jiang F, Kim SH. “Soft docking”: matching of molecular surface cubes. J Mol Biol. 1991;219(1):79–102.
   PubMed Web of Science ®Google Scholar
• Sherman W, Day T, Jacobson MP, et al. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 2006;49(2):534–553.
   PubMed Web of Science ®Google Scholar
• Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des. 2006;67(1):83–84.
   PubMed Web of Science ®Google Scholar
• Knegtel RM, Kuntz ID, Oshiro CM. Molecular docking to ensembles of protein structures. J Mol Biol. 1997;266(2):424–440.
   PubMed Web of Science ®Google Scholar
• Ivetac A, McCammon JA. Molecular recognition in the case of flexible targets. Curr Pharm Des. 2011;17(17):1663–1671.
   PubMed Web of Science ®Google Scholar
• Venkatraman V, Ritchie DW. Flexible protein docking refinement using pose-dependent normal mode analysis. Proteins. 2012;80(9):2262–2274.
   PubMed Web of Science ®Google Scholar
• Rueda M, Bottegoni G, Abagyan R. Consistent improvement of cross-docking results using binding site ensembles generated with elastic network normal modes. J Chem Inf Model. 2009;49(3):716–725.
   PubMed Web of Science ®Google Scholar
• Dietzen M, Zotenko E, Hildebrandt A, et al. On the applicability of elastic network normal modes in small-molecule docking. J Chem Inf Model. 2012;52(3):844–856.
   PubMed Web of Science ®Google Scholar
• Mangoni M, Roccatano D, Di Nola A. Docking of flexible ligands to flexible receptors in solution by molecular dynamics simulation. Proteins. 1999;35(2):153–162.
   PubMed Web of Science ®Google Scholar
• Lin JH, Perryman AL, Schames JR, et al. The relaxed complex method: accommodating receptor flexibility for drug design with an improved scoring scheme. Biopolymers. 2003;68(1):47–62.
   PubMed Web of Science ®Google Scholar
• Bajusz D, Ferenczy GG, Keseru GM. Discovery of subtype selective janus kinase (jak) inhibitors by structure-based virtual screening. J Chem Inf Model. 2016;56(1):234–247.
   PubMed Web of Science ®Google Scholar
• Lindert S, Li MX, Sykes BD, et al. Computer-aided drug discovery approach finds calcium sensitizer of cardiac troponin. Chem Biol Drug Des. 2015;85(2):99–106.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhai L, Lu W, et al. Discovery of novel allosteric eg5 inhibitors through structure-based virtual screening. Chem Biol Drug Des. 2016;88(2):178–187.
   PubMed Web of Science ®Google Scholar
• Tian S, Wang X, Li L, et al. Discovery of novel and selective adenosine a2a receptor antagonists for treating parkinson‘s disease through comparative structure-based virtual screening. J Chem Inf Model. 2017;57(6):1474–1487.
   PubMed Web of Science ®Google Scholar
• Viswanathan U, Tomlinson SM, Fonner JM, et al. Identification of a novel inhibitor of dengue virus protease through use of a virtual screening drug discovery web portal. J Chem Inf Model. 2014;54(10):2816–2825.
   PubMed Web of Science ®Google Scholar
• Starzec A, Miteva MA, Ladam P, et al. Discovery of novel inhibitors of vascular endothelial growth factor-a-neuropilin-1 interaction by structure-based virtual screening. Bioorg Med Chem. 2014;22(15):4042–4048.
   PubMed Web of Science ®Google Scholar
• Basciu A, Malloci G, Pietrucci F, et al. An enhanced-sampling md-based protocol for molecular docking. bioRxiv. 2018. DOI:10.1101/434092
   Google Scholar
• Verdonk ML, Mortenson PN, Hall RJ, et al. Protein-ligand docking against non-native protein conformers. J Chem Inf Model. 2008;48(11):2214–2225.
   PubMed Web of Science ®Google Scholar
• Bottegoni G, Rocchia W, Rueda M, et al. Systematic exploitation of multiple receptor conformations for virtual ligand screening. PLoS One. 2011;6(5):e18845.
   PubMed Web of Science ®Google Scholar
• Choi J, Choi KE, Park SJ, et al. Ensemble-based virtual screening led to the discovery of new classes of potent tyrosinase inhibitors. J Chem Inf Model. 2016;56(2):354–367.
   PubMed Web of Science ®Google Scholar
• Spyrakis F, Cavasotto CN. Open challenges in structure-based virtual screening: receptor modeling, target flexibility consideration and active site water molecules description. Arch Biochem Biophys. 2015;583(1 Oct):105–119.
   PubMedGoogle Scholar
• Ross GA, Morris GM, Biggin PC. One size does not fit all: the limits of structure-based models in drug discovery. J Chem Theory Comput. 2013;9(9):4266–4274.
   PubMed Web of Science ®Google Scholar